ES2757501T3 - Fusocinas que implican citocinas con afinidades de unión al receptor fuertemente reducidas - Google Patents
Fusocinas que implican citocinas con afinidades de unión al receptor fuertemente reducidas Download PDFInfo
- Publication number
- ES2757501T3 ES2757501T3 ES17195867T ES17195867T ES2757501T3 ES 2757501 T3 ES2757501 T3 ES 2757501T3 ES 17195867 T ES17195867 T ES 17195867T ES 17195867 T ES17195867 T ES 17195867T ES 2757501 T3 ES2757501 T3 ES 2757501T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- cytokine
- activity
- cytokines
- ifna2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306034 | 2013-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2757501T3 true ES2757501T3 (es) | 2020-04-29 |
Family
ID=48906191
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17195867T Active ES2757501T3 (es) | 2013-07-18 | 2014-07-03 | Fusocinas que implican citocinas con afinidades de unión al receptor fuertemente reducidas |
| ES14734831.2T Active ES2657060T3 (es) | 2013-07-18 | 2014-07-03 | Fusoquinas que implican citoquinas con afinidades de unión por el receptor fuertemente reducidas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14734831.2T Active ES2657060T3 (es) | 2013-07-18 | 2014-07-03 | Fusoquinas que implican citoquinas con afinidades de unión por el receptor fuertemente reducidas |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10640542B2 (enExample) |
| EP (2) | EP3299466B1 (enExample) |
| JP (2) | JP6580037B2 (enExample) |
| KR (1) | KR102322510B1 (enExample) |
| CN (2) | CN110835376B (enExample) |
| AU (2) | AU2014292371B2 (enExample) |
| BR (1) | BR112016001036B1 (enExample) |
| CA (1) | CA2917937C (enExample) |
| DK (1) | DK3299466T3 (enExample) |
| ES (2) | ES2757501T3 (enExample) |
| IL (1) | IL243451B (enExample) |
| MX (1) | MX375441B (enExample) |
| SG (2) | SG10201808738WA (enExample) |
| WO (1) | WO2015007536A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3371311B1 (en) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| CN109071632B (zh) | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| EP3455245A2 (en) | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| CN110114368B (zh) | 2016-10-24 | 2024-08-02 | 奥睿尼斯生物科学私人有限公司 | 靶向突变干扰素-γ及其用途 |
| KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| EP3576765B1 (en) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| CA3050601A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzm | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| CN117924493A (zh) | 2017-08-09 | 2024-04-26 | 奥里尼斯生物科学有限公司 | Clec9a结合剂及其用途 |
| EP3665201A4 (en) | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | CD8 BINDERS |
| EP3664829A4 (en) | 2017-08-09 | 2021-05-05 | Orionis Biosciences, Inc. | LIAISON OFFICERS AT PD-1 AND PD-L1 |
| WO2019089755A1 (en) | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| US12655186B2 (en) | 2018-01-26 | 2026-06-16 | Orionis Biosciences, Inc. | Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2 |
| CA3090406A1 (en) | 2018-02-05 | 2019-08-08 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| EP3833391A4 (en) | 2018-08-08 | 2022-08-10 | Orionis Biosciences, Inc. | ANTI-SIRP1ALPHA CHIMERIC PROTEINS AND USES THEREOF |
| EP3890773A4 (en) | 2018-11-08 | 2022-11-09 | Orionis Biosciences, Inc. | MODULATION OF DENDRITIC CELL LINES |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| CN113840833B (zh) | 2019-03-28 | 2025-06-17 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| WO2020198665A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Fibroblast activation protein binding agents and use thereof |
| US12544426B2 (en) | 2019-06-19 | 2026-02-10 | Orionis Biosciences, Inc. | Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes |
| CA3185087A1 (en) * | 2020-07-07 | 2022-01-13 | Nikolai Kley | Immunostimulatory adjuvants |
| JP2023552289A (ja) | 2020-11-19 | 2023-12-15 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法 |
| EP4329786A4 (en) | 2021-04-30 | 2024-12-11 | KaliVir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| WO2024112814A1 (en) * | 2022-11-21 | 2024-05-30 | Wisconsin Alumni Research Foundation | SYNTHETIC IL6-IL1β FUSION CYTOKINE FOR PROMOTING T CELL CYTOTOXIC FUNCTION, T CELL PROLIFERATION, AND TUMORICIDAL ACTIVITY |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0489116B1 (en) * | 1989-08-22 | 1994-04-06 | Immunex Corporation | Fusion proteins comprising gm-csf and il-3 |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| WO2001010912A1 (en) * | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| WO2002044394A2 (en) * | 2000-11-29 | 2002-06-06 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
| CN1168740C (zh) * | 2001-04-04 | 2004-09-29 | 上海美恩生物技术有限公司 | 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途 |
| EP1454138B1 (en) * | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| EP1598364A1 (en) * | 2004-05-21 | 2005-11-23 | AGIRx Limited | Chimerical soluble hyper IL-11 receptor and use thereof |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| US7947265B2 (en) * | 2006-08-02 | 2011-05-24 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| WO2008124086A2 (en) * | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| WO2009003145A1 (en) | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| CA2749558C (en) | 2008-12-08 | 2019-01-15 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| RU2583876C2 (ru) | 2009-08-17 | 2016-05-10 | Роше Гликарт Аг | Иммуноконъюгаты направленного действия |
| CN102497885A (zh) | 2009-09-10 | 2012-06-13 | 赛托斯生物技术公司 | 白介素-1β突变蛋白偶联物在糖尿病治疗中的用途 |
| EP2496607B1 (en) * | 2009-11-02 | 2017-09-27 | The Regents of The University of California | Vault complexes for cytokine delivery |
| CN108295087B (zh) * | 2009-12-23 | 2021-01-15 | 格兰达利斯有限公司 | 弗林蛋白酶敲减和gm-csf增强的(fang)癌症疫苗 |
| MX2012012229A (es) * | 2010-04-22 | 2013-03-05 | Yissum Res Dev Co | Leptinas de alta afinidad y antagonistas de leptina. |
| CN102372780A (zh) * | 2010-08-23 | 2012-03-14 | 上海市计划生育科学研究所 | 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用 |
| WO2012170072A1 (en) | 2011-06-06 | 2012-12-13 | Immungene, Inc. | Engineered antibody-tnfsf member ligand fusion molecules |
| CN104203982B (zh) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| WO2013107791A1 (en) * | 2012-01-20 | 2013-07-25 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
| PL2822575T3 (pl) | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
| PE20170908A1 (es) * | 2014-10-29 | 2017-07-12 | Teva Pharmaceuticals Australia Pty Ltd | VARIANTES DE INTERFERON a2b |
-
2014
- 2014-07-03 KR KR1020167002676A patent/KR102322510B1/ko active Active
- 2014-07-03 SG SG10201808738WA patent/SG10201808738WA/en unknown
- 2014-07-03 US US14/905,343 patent/US10640542B2/en active Active
- 2014-07-03 EP EP17195867.1A patent/EP3299466B1/en active Active
- 2014-07-03 MX MX2016000611A patent/MX375441B/es active IP Right Grant
- 2014-07-03 EP EP14734831.2A patent/EP3022305B1/en active Active
- 2014-07-03 AU AU2014292371A patent/AU2014292371B2/en active Active
- 2014-07-03 CN CN201911159381.7A patent/CN110835376B/zh active Active
- 2014-07-03 CN CN201480040538.3A patent/CN105705641B/zh active Active
- 2014-07-03 ES ES17195867T patent/ES2757501T3/es active Active
- 2014-07-03 SG SG11201600163VA patent/SG11201600163VA/en unknown
- 2014-07-03 ES ES14734831.2T patent/ES2657060T3/es active Active
- 2014-07-03 CA CA2917937A patent/CA2917937C/en active Active
- 2014-07-03 DK DK17195867T patent/DK3299466T3/da active
- 2014-07-03 WO PCT/EP2014/064227 patent/WO2015007536A2/en not_active Ceased
- 2014-07-03 BR BR112016001036-1A patent/BR112016001036B1/pt active IP Right Grant
- 2014-07-03 JP JP2016526515A patent/JP6580037B2/ja active Active
-
2016
- 2016-01-03 IL IL24345116A patent/IL243451B/en active IP Right Grant
-
2018
- 2018-06-01 AU AU2018203868A patent/AU2018203868B2/en active Active
- 2018-08-14 US US16/103,302 patent/US11358997B2/en active Active
-
2019
- 2019-08-27 JP JP2019154901A patent/JP6853317B2/ja active Active
-
2022
- 2022-04-29 US US17/733,026 patent/US12410222B2/en active Active
-
2025
- 2025-08-07 US US19/293,750 patent/US20260167687A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12410222B2 (en) | Fusokines involving cytokines with strongly reduced receptor binding affinities | |
| ES2986097T3 (es) | Proteínas de fusión de interleucina-2/receptor alfa de interleucina-2 y métodos de uso | |
| Han et al. | IL-15: IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization | |
| ES2763198T3 (es) | Moléculas que selectivamente activan las células T reguladoras para el tratamiento de enfermedades autoinmunes | |
| ES2717831T3 (es) | Variantes de IL-2 modificadas que activan selectivamente las células T reguladoras para el tratamiento de enfermedades autoinmunes | |
| KR101559330B1 (ko) | 암 및 만성 감염 치료를 위한, 효능제 활성을 갖는 인터루킨 2로부터 유도된 폴리펩티드 | |
| CN110437339A (zh) | 一种以白介素15为活性成分的融合蛋白型药物前体 | |
| ES2941234T3 (es) | Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos | |
| PT1076704E (pt) | Agonistas e antagonistas selectivos da il-2 | |
| KR20180100237A (ko) | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 | |
| JP2024543991A (ja) | Ｉｌ１０バリアントおよびその使用 | |
| CN105524147A (zh) | 重组聚多肽及其应用 | |
| US8716446B2 (en) | Biopolymer conjugates comprising an interleukin-11 analog | |
| JPH09512165A (ja) | インターロイキン１５ | |
| HK1252831B (en) | Fusokines involving cytokines with strongly reduced receptor binding affinities | |
| HK1225069B (en) | Fusokines involving cytokines with strongly reduced receptor binding affinities | |
| HK1225069A1 (en) | Fusokines involving cytokines with strongly reduced receptor binding affinities | |
| Pechenov et al. | Methods for preparation of recombinant cytokine proteins V. mutant analogues of human interferon-γ with higher stability and activity | |
| JP3689111B2 (ja) | インターロイキン１５ | |
| JP2007143555A (ja) | ポリペプチド |